Review
doi: 10.1158/1078-0432.CCR-10-1501.
Epub 2010 Aug 3.
HER2 fragmentation and breast cancer stratification
Affiliations
- PMID: 20682714
- DOI: 10.1158/1078-0432.CCR-10-1501
Item in Clipboard
Review
HER2 fragmentation and breast cancer stratification
Clin Cancer Res.
.
Abstract
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
Comment in
-
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.Clin Cancer Res. 2010 Aug 15;16(16):4226-35. doi: 10.1158/1078-0432.CCR-10-0410. Epub 2010 Jul 27. Clin Cancer Res. 2010. PMID: 20664024
Similar articles
-
p95HER2 and breast cancer.Cancer Res. 2011 Mar 1;71(5):1515-9. doi: 10.1158/0008-5472.CAN-10-3795. Epub 2011 Feb 22. Cancer Res. 2011. PMID: 21343397 Review.
-
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.N Engl J Med. 2006 May 18;354(20):2103-11. doi: 10.1056/NEJMoa054504. N Engl J Med. 2006. PMID: 16707747 Clinical Trial.
-
Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.Breast Cancer Res Treat. 2010 Feb;120(1):217-27. doi: 10.1007/s10549-009-0469-z. Epub 2009 Jul 21. Breast Cancer Res Treat. 2010. PMID: 19629680
-
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.Clin Cancer Res. 2005 Jun 15;11(12):4357-64. doi: 10.1158/1078-0432.CCR-04-2107. Clin Cancer Res. 2005. PMID: 15958618
-
P95 HER2 fragments and breast cancer outcome.Expert Rev Anticancer Ther. 2014 Sep;14(9):1089-96. doi: 10.1586/14737140.2014.929946. Epub 2014 Jun 26. Expert Rev Anticancer Ther. 2014. PMID: 24968823 Review.
Cited by
-
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.Cancer Res. 2013 Feb 15;73(4):1411-9. doi: 10.1158/0008-5472.CAN-12-2149. Epub 2012 Dec 17. Cancer Res. 2013. PMID: 23248119 Free PMC article.
-
Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.J Mol Model. 2013 Jul;19(7):2797-810. doi: 10.1007/s00894-012-1638-2. Epub 2012 Nov 10. J Mol Model. 2013. PMID: 23143677
-
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.Breast Cancer Res. 2015 Aug 19;17(1):113. doi: 10.1186/s13058-015-0624-x. Breast Cancer Res. 2015. PMID: 26285572 Free PMC article.
-
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.Oncogene. 2013 May 9;32(19):2463-74. doi: 10.1038/onc.2012.256. Epub 2012 Jul 2. Oncogene. 2013. PMID: 22751112 Free PMC article.
-
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform.Cancers (Basel). 2022 Oct 5;14(19):4859. doi: 10.3390/cancers14194859. Cancers (Basel). 2022. PMID: 36230782 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
